Table 2 Subgroup analysis of efficacy endpoints
Subgroups | MET-specific alterations | Canonical alterations | Pan-alterations | |||
|---|---|---|---|---|---|---|
ctDNA Negative | ctDNA Positive | ctDNA Negative | ctDNA Positive | ctDNA Negative | ctDNA Positive | |
V0 | ||||||
Rate | 51.7% | 48.3% | 51.7% | 48.3% | 24.1% | 75.9% |
ORR (95% CI) | 60.0% (35.2–84.8%) | 50.0% (23.0–77.0%) | 60.0% (35.2–84.8%) | 50.0% (23.0–77.0%) | 71.4% (29.0–96.3%) | 50.0%(28.2–71.8%) |
mPFS, m (95% CI) | 7.5 (6.0–20.2) | 4.9 (2.2-NA) | 7.5 (6.0–20.2) | 4.9 (2.2-NA) | 7.7 (6.0-NA) | 6.0 (3.0–9.2) |
mOS, m (95% CI) | 27.6 (11.8-NA) | 9.5 (8.2-NA) | 27.6 (11.8-NA) | 9.5 (8.2-NA) | NA (16.3-NA) | 27.6 (8.2-NA) |
V1 | ||||||
Rate | 70.0% | 30.0% | 75.0% | 25.0% | 34.5% | 65.5% |
ORR (95% CI) | 64.3% (35.1–87.2%) | 16.7% (4.0–64.1%) | 60.0% (35.2–84.8%) | 20.0% (5–71.6%) | 71.4% (29.0–96.3%) | 38.5% (13.9–68.4%) |
mPFS, m (95% CI) | 7.9 (6.0-NA) | 2.2 (2.2-NA) | 7.9 (6.0-NA) | 2.2 (2.2-NA) | 8.2 (4.1-NA) | 6.0 (3.0-NA) |
mOS, m (95% CI) | 16.3 (9.2-NA) | NA (7.8-NA) | 16.3 (9.2-NA) | NA (7.8-NA) | 16.3 (6.3-NA) | NA (9.2-NA) |
Longitudinal Pan-mutation Dynamics | ||||||
mPFS for ctDNA Negative, m (95% CI) | 6.8 (5.9-NA) | 6.8 (5.9-NA) | 7.1 (6.0-NA) | |||
mPFS for ctDNA Residual, m (95% CI) | 2.2 (2.2-NA) | 2.2 (2.2-NA) | 5.9 (3.0–6.0) | |||
mPFS for ctDNA Clearance, m (95% CI) | 9.3 (6.0-NA) | 9.3 (6.0-NA) | 8.5 (4.1-NA) | |||
